CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Eunyoung Kang(University of Calgary), Angela Brooks‐Wilson(BC Cancer Agency), Julie M. Cunningham(Cancer Research UK), Nicola S. Meagher(The University of Sydney), Neil Lambie(New South Wales Department of Health), Mona A. El‐Bahrawy(Hammersmith Hospital), Linda S. Cook, Rhonda Farrell(Prince of Wales Hospital), Esther Elishaev(University of Pittsburgh), Penny Coulson(Institute of Cancer Research), Michael E. Carney(The University of Texas MD Anderson Cancer Center), Adelyn Bolithon(Cancer Institute of New South Wales), Michael S. Anglesio(University of British Columbia), Christiani Bisinotto(Universidade de São Paulo), Gregg Nelson(Brigham and Women's Hospital), Marjorie J. Riggan(Duke Medical Center), Beyhan Ataseven(Kliniken Essen-Mitte), C. Blake Gilks(Vancouver General Hospital), Ashley Weir(The University of Melbourne), Paul A. Cohen(The University of Western Australia), Ellen Barlow(Royal Hospital for Women), Matthias W. Beckmann(Universitätsklinikum Erlangen), Joshua Millstein(University of Southern California), Prafull Ghatage(University of Calgary), Simon A. Gayther(The University of Texas Health Science Center at Houston), Sara Y. Brucker(University Children's Hospital Tübingen), Aleksandra Gentry‐Maharaj(UCL Australia), Anna Fischer(University of Tübingen), Alicia Cazorla(Hospital Universitario Fundación Jiménez Díaz), Sián Fereday(Peter MacCallum Cancer Centre), Daniel W. Cramer(Brigham and Women's Hospital), Jessica Boros(The University of Sydney), Gordana Popović(The University of Sydney), Yovanni Casablanca(Levine Cancer Institute), Madeleine Courtney‐Brooks(University of Virginia Health System), Kyo Farrington(University of Calgary), Alison H. Brand(The University of Sydney), Katrina Tang(Prince of Wales Hospital), Thomas P. Conrads(Inova Health System), Philip Crowe(UNSW Sydney), Kathleen M. Darcy(Gynecologic Oncology Group), Cezary Cybulski(International Hereditary Cancer Center), Betty Leung(UNSW Sydney), Ramona Erber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Hans Bösmüller(University of Tübingen), María J. García(Spanish National Cancer Research Centre), Cheng‐Han Lee(University of Alberta), Jennifer Alsop(Manchester Academic Health Science Centre), Jessica Berger(University of Pittsburgh)
Cited by 46
Related Papers
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
|Nature Genetics|1999|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k